FibroGen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (HIF) biology to generate clinical programs targeting multiple therapeutic areas. FibroGen's most advanced product candidate, roxadustat (FG-4592), is an oral small molecule inhibitor of HIF prolyl hydroxylases (HIF-PHs), in Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD). Our second product candidate, FG-3019, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer and liver fibrosis.

San Francisco, US
Size (employees)
364 (est)+4%
FibroGen was founded in 1993 and is headquartered in San Francisco, US

FibroGen Office Locations

FibroGen has an office in San Francisco
San Francisco, US (HQ)
409 Illinois St

FibroGen Data and Metrics

FibroGen Financial Metrics

FibroGen's revenue was reported to be $179.6 m in FY, 2016 which is a 1% decrease from the previous period.

Revenue (FY, 2016)

179.6 m

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

(61.7 m)

EBIT (FY, 2016)

(53.7 m)

Market capitalization (26-Jun-2017)

2.3 b

Closing share price (26-Jun-2017)


Cash (31-Dec-2016)

173.8 m
FibroGen's current market capitalization is $2.3 b.
USDFY, 2015FY, 2016


180.8 m179.6 m

Revenue growth, %


R&D expense

214.1 m187.2 m

General and administrative expense

44.4 m46 m

Operating expense total

258.5 m233.2 m


(77.6 m)(53.7 m)

EBIT margin, %


Interest expense

(11 m)(10.7 m)

Pre tax profit

(85.5 m)(61.8 m)

Income tax expense

242 k(71 k)

Net Income

(85.8 m)(61.7 m)
USDFY, 2015FY, 2016


153.3 m173.8 m

Accounts Receivable

15.4 m10.4 m


4 m2.9 m

Current Assets

200.6 m266.5 m


129 m123.7 m

Total Assets

470.6 m469.6 m

Accounts Payable

6.5 m6.2 m

Current Liabilities

67.2 m65.1 m

Additional Paid-in Capital

586.6 m625.9 m

Retained Earnings

(408.1 m)(469.7 m)

Total Equity

177.6 m155.8 m

Financial Leverage

2.7 x3 x
USDFY, 2015FY, 2016

Net Income

(85.8 m)(61.7 m)

Depreciation and Amortization

5.7 m6 m

Accounts Receivable

(2 m)5 m


978 k1.1 m

Accounts Payable

2 m(298 k)

Cash From Operating Activities

(18.6 m)7.1 m

Purchases of PP&E

(2 m)(1.3 m)

Cash From Investing Activities

(5.9 m)6.6 m

Cash From Financing Activities

12.3 m6.7 m
USDY, 2016


508.7 k

Financial Leverage

3 x

FibroGen Operating Metrics

FibroGen's Facilities was reported to be 2 in FY, 2016
FY, 2016

Phase III Trials


Phase II Trials




Patent Portfolios


FibroGen Market Value History

FibroGen Revenue Breakdown

FibroGen Online and Social Media Presence

FibroGen Company Life and Culture

You may also be interested in